INTRODUCTION
Development and validation of early-response radiation injury biomarkers are critical for effective triage of irradiated individuals. The early medical management situation requires quantitative indications for early initiation (within 1 d after radiation exposure) of cytokine therapy in individuals exposed to life-threatening radiation doses with bone marrow (BM) acute radiation sickness (ARS) as well as effective triage tools for first-responders in mass-casualty radiological incidents (1, 2) . Past experiences (i.e. nuclear detonations in Hiroshima and Nagasaki; Chernobyl reactor incident) or terrorist attacks could expose large numbers of people to ionising radiation. In accidental irradiation situations, it is necessary to evaluate the radiation dose received by the victim, to assess the damage to the critical systems (BM, gastrointestinal, etc.), monitor the recovery stage and make accurate predictions for possible ARS outcome (3) . Radiation management of such events requires rapid and accurate biodosimetry with a precision as high as possible to determine risk for morbidity and mortality (1) . Radiation-responsive proteins as well as their combination with haematological biomarkers have been suggested as biomarkers for use in radiation exposure assessments (4 -10) . It was demonstrated that use of multiple proteins along with classical biodosimetric methods enhances the specificity and diagnostic utility for early assessment of radiation exposure. Haematological biomarkers of exposure to ionising radiation are well characterised and used in medical management of radiological casualties (11) . Measurements of lymphocyte depletion kinetics (12, 13) and time-and radiation severity changes in neutrophil cell counts observed after irradiation (14) provide clinical information soon after exposure. However, the accurate radiation exposure dose estimation by lymphocyte depletion kinetics or counting chromosome aberrations becomes problematic after doses close to the LD 50 , and certainly for higher doses due to significant declines (,200 cells mm 23 ) in peripheral lymphocyte counts by 24 h and inhibition of mitogen stimulated lymphocyte cell division, which is necessary for metaphase chromosome aberration analysis.
Radiation-responsive protein levels show considerable potential as biodosimeters for the rapid assessment of radiation dose absorbed (15 -17) . Tissue-specific protein biomarkers detected in peripheral blood can provide diagnostic information of organ-specific radiation injury (18, 19) . Multi-parametric approach combining Flt3L levels and haematology has been compared with cytogenetic analysis to demonstrate a clinical utility in assessing a haematopoietic syndrome in radiation accident victims (3) . Acute-phase proteins, whose concentrations are significantly increased during the acute-phase response, have been extensively investigated and shown to play an essential role in injuries caused by radiation in animals (15, 20 -25) and humans (16, 25) . Additional studies in nonhuman primates (NHP) (15, 21) and rabbits (23) show that dynamics and content of C-reactive protein (CRP) exactly reflect the course and severity of ARS, as well as demonstrating its ability to play a role as a prognostic ARS indicator.
Early (within hours) dose-dependent radiationinduced increases of haematopoietic cytokines and growth factors are associated with a wide-ranging systemic response that includes fever, increasing production Published by Oxford University Press 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Radiation Protection Dosimetry (2014), Vol. 159, No. 1-4, pp. 61 -76 doi:10.1093/rpd/ncu165 Advance Access publication 12 June 2014 and differentiation of BM cells and dramatic expression of acute-phase proteins (26) . These cytokines and growth factors have been shown to be essential contributors to natural resistance to lethal irradiation, and their expression in vivo showed a significant effect on haematopoietic recovery after radiation (27 -29) . Flt3L is one of the most important cytokines for regulation of the haematopoietic system, and its receptor is expressed on both stem cells and progenitors. In synergy with other growth factors, Flt3L stimulates the proliferation and differentiation of various blood cell progenitors (30) . Support for the medical radiological countermeasure clinical potential of Flt3L has been demonstrated in vivo where Flt3L alone, or in combination with granulocyte colonystimulating factor, protected rabbits against the effects of total-body irradiation (TBI) on the stem cell compartment (31) . Flt3L was advocated by Bertho and colleagues for use as a biomarker of radiation-induced BM aplasia, which is characterised by the disappearance of stem cells and progenitors from the BM (3, 18) . The authors' research is focused to investigate the diagnostic utility of proteomic biomarkers combined with haematological bioindicators for radiation dose and injury assessment using murine and NHP radiation models with potential applications in humans. The authors have reported results from murine (BALB/c, males) TBI with 60 Co gamma ray (0.10 Gy min
21
) model studies to analyse simultaneously multiple proteins selected from distinctly different pathways (i.e. Growth Arrest and DNA Damage Inducible Gene 45 protein or GADD45a, IL-6 and SAA) and showed, for the first time, that a protein expression profile can be developed not only to predict radiation exposure in mice but also to distinguish the level of radiation exposure, ranging from 1 to 7 Gy. The use of multiple protein targets was evaluated using multiple linear-regression analysis to provide dose -response calibration curves for dose assessment with a threshold for gamma-exposure detection of 2 Gy. Multivariate discriminant analysis demonstrated enhanced dose-dependent separation of irradiated animals from control as the number of biomarkers increased (7) . The combination of only one protein (SAA) with haematological biomarkers (lymphocytes and ratio of neutrophils to lymphocytes) demonstrated (1) enhanced separation of 1-Gy irradiated animals from controls and between different combinations of doses and (2) improvement of the threshold for gamma-exposure detection up to 1 Gy compared with the selected protein profile only (8) . Herein, the authors present results for plasma proteomic profile (CRP, SAA, IL-6 and Flt3L) evaluated using multivariate linear-regression analysis to provide dose-response calibration curves for photon-radiation dose assessment in 30 rhesus macaques total-bodyirradiated to a broad dose range of 1-8.5 Gy with 60 Co gamma rays (0.55 Gy min 2 1 ). Equations for radiation dose received were established based on different combinations of proteins at sample collection timepoints 6 h, 1, 2, 3, 4 and 7 d post-TBI. The prognostic utility of plasma Flt3L levels 3 d after exposure to assess BM injury measured by the nadir neutrophil count after radiation exposure is also discussed. w restraint chair and irradiated bi-laterally. Animals representing sham (n ¼ 6) were also treated the same except they were not exposed to radiation.
MATERIALS AND METHODS

Model
At designated sampling time-points (i.e. from 6 h to 60 d) after exposure, peripheral blood from the saphenous vein was drawn from NHPs, sometimes while under anaesthesia. Drawn blood was collected into a serum separator microtainer and potassium EDTA vacutainer tubes (Becton, Dickinson and Company, Franklin Lakes, NJ, USA). Blood in EDTA tubes for white blood cell count measurements was analysed within several hours after biosampling. For protein measurements, tubes with collected peripheral blood were centrifuged at 800 g (4 8C) for 10 min to isolate the plasma and cell pellets. Blood sample aliquots were stored frozen (-80 8C) until analysis.
Protein bioassays
Sandwich ELISA for monkey CRP was performed using a commercially available kit (Life Diagnostics, Inc., West Chester, PA, USA) according to the manufacturer's instructions. The limit of detection (LOD) for the assay was 0.8 ng ml 21 . Sandwich ELISA for monkey SAA was performed using a commercially available kit (Life Diagnostics, Inc., West Chester, PA, USA). The LOD for the assay was 0.5 ng ml 21 .
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Quantification of IL-6 was performed using a monkey IL-6 ELISA kit (Cell Sciences, Inc., Canton, MA, USA). The sensitivity for the assay was 1 pg ml 21 . Quantification of Flt3L was performed using the human ELISA kit, which cross-reacts with monkey Flt3L, according to the manufacturer's recommendations (R&D Systems, Minneapolis, MN, USA). The LOD for the assay was 7 pg ml 21 . Three replicate measurements were determined for each sample and standards. The optical density was measured using a spectrophotometer (BIO-TEK Instruments, Inc., Winooski, VT, USA). The CRP, SAA, IL-6 and Flt3L concentrations in plasma samples were determined via use of Table Curve 2D software (Systat Software, Inc., San Jose, CA, USA), as previously described (9, 10) .
Peripheral blood cell counts
Complete blood cell counts and differentials were determined using a clinical haematology analyser (Bayer Advia 120, Bayer, Tarrytown, NY, USA), as previously described (5) .
Statistical data analysis
Statistical software (Statistica-StatSoft, Tulsa, OK, USA) was used for statistical data analysis. Multivariate analysis of variance Wilks' Lambda statistics was used when comparing more than two groups, and two-sided Student's t test was used when comparing two groups to determine significant difference among sampling timeand dose-points. P-values of ,0.05 were considered statistically significant. Values are expressed as mean+ standard error (SE). Multiple linear-regression analysis was used to develop dose-response relationships for multiple protein inductions for radiation dose assessment. To study the dependence of each biomarker on dose assessment, the analysis was performed according to following model:
where Y variable (dose assessment) can be expressed in terms of a constant (a) and a slope (b) times the X variables (protein expression data), p is the number of protein biomarkers in the model. Sum of the absolute values of residuals (the difference between the given TBI dose and the estimated value) for the radiation dose prediction was created for each sample collection time-point. As an example, sum of the absolute values of residuals for the radiation dose prediction 1 d post-TBI is shown in Table 1 . Receiver operating characteristic (or ROC curve) analysis of single and combination of biomarkers was performed using ROCCET on-line tool (32) . Individual markers were analysed using classical ROC and multiple markers with partial least-squares discriminant analysis approach. The area under the curve (AUC) with confidence intervals was used to demonstrate the sensitivity and specificity of the proposed protein biomarkers to reflect sub-group differences.
RESULTS
Experimental data
The radiation-induced Flt3L levels increased in a doseand time-dependent manner ( Figure 1 ). Baseline level of Flt3L in plasma of non-exposed animals (n ¼ 24) was log-normally distributed with a highest probability Flt3L value of 12.6 (+6.8) pg ml In animals from 6.5-Gy cohort, pre-TBI Flt3L level was spanning from 5.7 (+3.4) to 18.4 (+3.7) pg ml 21 . At Day 1, Flt3L level was significantly elevated (P ¼ 0.00097) and spanned from 47.8 (+3.5) to 87.4 (+6.9) pg ml 21 with a mean value and a standard deviation (SD) of 62.6 (+15.9) pg ml 21 for all six animals (data not shown). Time-dependent increase persisted and spanned from 582.9 (+10.9) to 1187.7 (+118.6) pg ml 21 with a mean value and an SD of 855.2 (+236.8) pg ml 21 for all six animals at Day 7 ( Figure 1D ). In animals from 8.5-Gy cohort, pre-TBI Flt3L level was spanning from 35.1 (+3.5) to 72.3 (+3.6) pg ml 21 . At Day 1, Flt3L level was significantly elevated (P ¼ 0.0037) and spanned from 47.4 (+3.5) to 159 (+4.1) pg ml 21 with a mean value and an SD of 85.8 (+40.6) pg ml 21 for all six animals (data not shown). Time-dependent increase persisted and spanned from 853.4 (+11.8) to 1311.5 (+136.3) pg ml 21 with a mean value and an SD of 1097.3 (+182.2) pg ml 21 for all six animals at Day 7 ( Figure 1D ). Flt3L levels were peaking 2 d before euthanasia in the 6.5-and 8.5-Gy groups. Peak Flt3L levels reached the ranges of 894.6 to 1476.6 pg ml 21 and from 1678.4 to 2852.9 pg ml 21 for the 6.5-and 8.5-Gy groups, respectively. These peak levels correlated with neutrophil counts (R ¼ 0.944 and 0.972, respectively).
The prognostic ability of early-phase Flt3L levels to predict the severity of BM injury was evaluated. Neutrophil counts at nadir were used here as an indicator of BM aplasia severity induced by radiation in this model. Baseline levels and 95 % confidence levels (CLs) of neutrophils were 2.64 (0.04 -5.23)`Â10 9 l 21 . Following exposure to graded doses of radiation, the neutrophil count progressively decreased, reaching a nadir at 11 -23 d after exposure, followed by a recovery in survived animals. The time at nadir decreases progressively from 23 to 11 d after exposure as radiation dose increases from 3.5 to 8.5 Gy. Plasma levels of Flt3L measured 3 d after exposure to graded radiation doses were compared with neutrophil counts at nadir ( Figure 2 ). The fitted curve in Figure 2 reflects a least-squares regression fit of the data to a sigmoidtype model function with coefficients as shown in the following equation with correlation coefficient of R ¼ 0.992:
where x is neutrophil counts at nadir and y is a Flt3L level at 3 d. Flt3L levels are low (,40 pg ml
21
) at baseline levels of neutrophils. Radiation causes a progressive decrease in nadir neutrophil counts, which is correlated with progressive increases in Flt3L levels at 3 d until Flt3L levels reach a maximum level some 7-fold higher ( 280 pg ml 21 ) than baseline and neutrophil counts (0.01`Â 10 9 l
) some two orders of magnitude less than sham-treated animals.
These new Flt3L results were combined with recently presented results from the same NHP model, in which the authors demonstrated dose-and time-dependent changes in blood of three proteins with the different time-window expressions: CRP, SAA and IL-6 measured by ELISA (9) . Briefly, the radiation-induced IL-6 levels peaked at 6 h in a dose-dependent manner and returned to a baseline level at Day 2 in 1-and 3.5-Gy cohorts. The second-phase elevations were observed in animals from 6.5-and 8.5-Gy cohorts and were found strongly correlated with ARS outcome. Highly significant elevations of CRP and SAA (P ¼ 0.00017 and 0.0024, respectively) were found in animal plasma at 6 h after all TBI doses suggesting their potential use as early-phase biodosimeters. The mean relative SAA content normalised on pre-TBI level was found 400-fold elevated in the 1-Gy animal cohort 1 d after TBI (9) . In this study, two phases in CRP and SAA expressions have been found in NHPs after TBI to the lethal doses 6.5 and 8.5 Gy and that the dynamics and content of CRP and SAA levels reflect the course and severity of the ARS and may function as prognostic indicators of ARS outcome (9) .
Multivariate linear-regression analysis results for radiation dose assessment
Equations for radiation dose received were established using the multivariate linear-regression analysis based on different combinations of proteins (CRP, SAA, IL-6 and Flt3L) at sample collection time-points 6 h, 1, 2, 3, 4 and 7 d post-TBI. Table 1 demonstrates regression analysis method results of finding a line of 'best fit' to a set of data by minimising the sum of residual values. Shaded areas represent the sum residual minimum values for different biomarkers or their combinations. Either CRP or its combination with SAA might be used as a first-screening test to distinguish the control (sham) group from irradiated cohorts. Given dose was defined as a nominal irradiation dose based on physical dosimetry in the experiments; predicted dose was defined as a dose estimated in analysis; residual is difference between the predicted and given doses.
At 6 h post-irradiation, based on lymphocyte counts alone, given TBI doses of 1, 3.5 and 8.5 Gy were predicted as 3.1 (þ0.7/20.3), 3.8 (þ0.6/20.3) and 3.9 (þ0.3/20.8) Gy at 95 % CL, respectively (data not shown). By adding the IL-6, an early-responding biomarker in the progressive dose-dependent manner (9) , the accuracy in dose prediction improved and gave predictions of 1.6 (þ0.6/20.6), 3.0 (þ0.5/21.0) and 7.6 (þ3.9/23.6) Gy, respectively. Table 2 shows the best biomarker combinations to predict the given irradiation dose. Predicted dose (Y ) values are shown as means+SDs. Outliers marked as (*) were defined as values that fell out of 95 % CL. At 6 h post-irradiation, three equations might be used for the dose estimation: (1) CRP alone [2] , (2) its combination with IL-6 [5] or (3) combinations of all proteins [15] (Table 2 ). Using the combination of IL-6, CRP, SAA and Flt3L [15] significantly improved the irradiation dose prediction (Figure 2A ). (Table 2) . Outliers in 0-Gy cohort (1.62 Gy for [9] , 1.73 Gy for [12] and [15] ) are for the same reason mentioned earlier. In 1-Gy cohort, overestimated dose of 3.2 Gy using equation [9] ) in one animal from the 1-Gy cohort. The compensatory effect for overestimated dose was observed after adding SAA results; however, the underestimated doses were still present (0.2 Gy for [12] and 0.22 Gy for [15] ) ( Table 2) .
Beginning Given dose is the nominal irradiation dose based on physical dosimetry in the experiments; predicted dose is a dose estimated in analysis; residual is difference between the predicted and given doses; SE of predicted dose is accuracy for predicted dose at 95 % CL and P-level of the dose prediction. Table 4 shows the residuals (the absolute difference between given and predicted dose) and accuracy in dose prediction for the best combination of biomarkers [15] .
Results from multivariate ROC analysis to demonstrate the sensitivity and specificity of the proposed protein biomarkers to compare sham vs. animal irradiated to 1 Gy are shown in Table 5 . At least two or more single or combinations of biomarkers with AUCs !0.8 are seen at each time-point after exposure to radiation. In general, combinations that included Flt3L had higher AUCs than combinations without Flt3L. 
DISCUSSION
The authors previously established animal (Mus musculus, M. mulatta) radiation models to evaluate radiation biomarkers for future application to humans and reported that protein expression profile measured in samples collected 1-3 d after TBI can successfully predict the dose in photon-exposed animals (8 -10) . In the mouse radiation model, results from ongoing studies demonstrate successful radiation dose assessment using haematological and protein profiles in 'blinded' tests. Results for those studies and results presented in this paper demonstrate proof-of-concept that these biomarkers are sufficient for a fast and accurate triage of individuals assessed from 6 h up to 7 d after exposure. It was demonstrated that protein expression profiles could be developed not only to assess radiation exposure in rhesus macaques but also to distinguish the level of photon-radiation exposure, ranging from 1 to 8.5 Gy at sample collection timepoints from 6 h to 7 d post-TBI. It was demonstrated that in rhesus macaques, the conventional biodosimetry method based on lymphocyte counts alone was not Given dose is the nominal irradiation dose based on physical dosimetry in the experiments; predicted dose is a dose estimated based on multiple proteins using the multiple linear-regression analysis; residual is difference between the predicted and given doses; SE of predicted dose is accuracy for predicted dose at 95 % CL.
successful to predict the exposure dose from 1 to 8.5 Gy, whereas the combination of proteins with different time-window expressions can not only predict the exposure dose but serve as prognostic indicators of ARS severity and radiation sickness outcome. The serum concentrations of the rapid responding acute-phase proteins SAA and CRP increase within few hours after irradiation. Either CRP or SAA might be used as a first-screening test to distinguish the control (sham) group from animals from 1-Gy cohort (Table 1) . However, CRP level of 81.7 mg ml 21 in one animal from control group that had acute inflammatory process on his fingers and allergic reaction around his eyes was found overlapped with results for the 1-Gy cohort, reflecting the fact that ROC curve analysis demonstrated a sensitivity of 100 % and specificity of 98.7 % to discriminate CRP results for the 1-Gy cohort from 75 control/baseline cases (9) . The authors currently perform additional studies in the mouse TBI model to address stress effect, infection, burn or wound trauma, and their combinations with irradiation in order to understand the effect of any confounders. It is important because a radiological or nuclear event would be expected to involve victims with mixed injuries as well as individuals with unrelated underlying pathologic processes. Use of a panel of biomarkers derived from different pathways can assist in resolving some of these confounders. The authors have earlier suggested the use of CRP and SAA as a triage assay in the case of mass radiological casualty incidents based on nonhuman TBI studies (5, 9) . The primary triage diagnostic assay must be rapid, ideally self-administered, minimally invasive and readily identify all (i.e. no false negatives) radiation-exposed individuals. Since the desired results of this primary triage diagnostic assay are to identify candidate individuals for high-priority further diagnostic testing, a small percentage of false-positives are acceptable (9) . CRP and SAA normal concentration in healthy human serum is usually ,10 and 20 mg ml
21
, respectively, slightly increasing with age (33 -36) . In triage, people with severe bacterial infection and burns, CRP and SAA level might be .200 mg ml 21(37, 38) and it might cause false-positive dose estimation. SAA appears to be a clinically useful marker of inflammation in acute viral infections (95-150 mg ml
), without significant changes in the CRP concentration (5-35 mg ml 21 ) (39) . Others have suggested that CRP and SAA examined together can distinguish bacterial from viral infection (38) . Available data suggest that CRP values are always higher in acute bacterial infection than in viral infection. In the case of chronic inflammation (e.g. arthritis), increased serum concentrations of acute-phase proteins are generally observed but their increase is lower than during acute episodes (36, 38) . The authors' recent results reveal two phases in CRP expression following irradiation to lethal doses. Further, the authors' results demonstrated that the dynamics and content of CRP predict the severity of ARS (9) and are in a good agreement with other results demonstrated in rhesus monkeys exposed to TBI 60 Co gamma rays (21, 15, 24) . Using a capillary precipitation of specific C-reactive antiserum method, the most sensitive existing method at that time, CRP was reported in mm of precipitated complexes (21, 15) . Mal'tsev and colleagues used the same method to predict a prognosis of ARS outcome in 147 Chernobyl nuclear power plant accident patients during primary reaction to the irradiation (1-2 d after) and in the latent period of radiation disease (3-9 d after) (16) . Currently available methods for CRP detection (i.e. FDA-approved home-use and hand-held devices for measurement of CRP based on ELISA methodology, latex-enhanced immunonephelometric methods, automated immunoturbidimetric and immunoluminometric assays, or the latex-agglutination turbidimetric immunoassay) are much better sensitive. It was estimated that 1 mm of CRP-precipitated complexes is approximately equivalent to 100 mg ml 21 of the ELISA-based assays. According to CRP indexes reported in Chernobyl victims as early as 1-2 d after exposure, the good prognosis for survival was reported in people with 0.6(+0.1) mm of CRP-precipitated complexes (16) , which is equivalent to 50-70 mg ml 21 of CRP content in ELISA-based assays. The poor survival prognosis was reported in victims with 2.1(+0.2) mm (16) , which is equivalent to 190-230 mg ml
. As for the latent period of radiation sickness (3-9 d after), Time postirradiation the good prognosis for survival was reported in people with 0.3(+0.1) mm of CRP-precipitated complexes (16) , which is equivalent to 20-40 mg ml 21 of CRP content in ELISA-based assays. The poor survival prognosis was reported in victims with 1.4(+0.2) mm (16) , which is equivalent to 120-160 mg ml 21 . In normal individuals, serum levels of Flt3L are relatively low (,100 pg ml 21 ) (40, 41) and are reported slightly increased up to 150 pg ml 21 in runners at the end of a marathon race (42) . Elevated levels of Flt3L (,10 ng ml
) have been noted in certain stem cell or progenitor cell disorders such as Fanconi anaemia and acquired aplastic anaemia (40, 43) . While early-phase (1-7 d after radiation exposure) Flt3L levels and other plasma biomarkers can serve as effective diagnostic biodosimeters for radiation dose assessment, the biomarker can also be used as a prognostic indicator of radiationinduced BM severity. Using a NHP radiation model, Bertho and colleagues showed that plasma Flt3L levels at 5 d were correlated both with radiation dose and with the severity of radiation-induced aplasia, which included an assessment of nadir neutrophil counts (18) . That NHP study involved TBI (2 Gy, n ¼ 2; 4 Gy, n ¼ 2; 6 Gy, n ¼ 1 and 8 Gy, n ¼ 1) as well as unilateral irradiation (6.5 Gy, n ¼ 2). The results shown here using a TBI model and correlating early-phase Flt3L levels with neutrophil counts at nadir are in agreement with their findings, but the increase in animal replicate numbers (n ¼ 6) provides far greater detail towards the development of diagnostic algorithms for prediction of radiation-induced BM injury by early-phase biomarker measurements. Increases in plasma Flt3L in the earlyphase (3-5 d) after radiation exposure were shown to be predictive of the severity of BM aplasia.
Most radiation accidents typically involve partialbody exposures (44) , which can be a major confounder in the assessment of radiation dose. In a mouse heterogeneous radiation model, Flt3L levels showed diagnostic utility as a bioindicator of BM aplasia severity (45) . Huchet and colleagues advocated monitoring of plasma Flt3L levels to predict BM injury severity during the course of local fractionated radiotherapy (46) . Plasma Flt3L levels were also shown to increase rapidly after a conditioning regimen involving use of cyclophosphamide and radiation, for patients prior to haematopoietic stem cell transplantation, and were correlated with the duration of pancytopenia (47) . Monitoring of plasma Flt3L levels both during the early and delayed analysis has been applied to assess the severity of BM aplasia in radiation accidents (3) . Early-phase dose assessment diagnostic approaches based on monitoring biomarkers that can contribute to a TBI equivalent dose as well as an indicator of radiation injury severity to a relevant organ system have significant merit. Here, early-phase (3 d after exposure) plasma Flt3L levels show these dual diagnostic benefits.
There are limited data to compare Flt3L radioresponses between NHP and humans. Bertho and colleagues earlier reported Flt3L levels in a human accidentally exposed to radiation with a dose estimated between 4.2 and 4.8 Gy based on cytogenetic evaluation (3) . Unfortunately, bioassay sampling in these cases was initiated only 20 d after exposure. Nadir of neutrophil counts was recorded 28 d after exposure, when cytokine treatment was initiated and was coincident with Flt3L levels of 3200 pg ml 21 . This case is best compared with the 6.5 Gy NHP cohort described in this report. At neutrophil nadir (15 d after exposure), peak Flt3L levels were 1476 pg ml
; however, neutrophil counts in both the accident case (28 d) and 6.5 Gy NHPs (15 d) were comparable (0.04`Â 10 9 l
). Plasma proteomic biodosimetry assays should be applied in future radiation accidents to accumulate a data set to establish a human radiation calibration curve, similar to that done for lymphocyte count and depletion kinetics (13) . In the authors' ongoing research in B6D2F1 female mouse TBI model, Flt3L was not found elevated in blood of mice challenged with stress, infection or trauma (15 % non-lethal total-body surface skin burns or wounds) performed within 1 h after radiation injury. Those findings suggest that Flt3L is a highly radiation-specific biomarker. In addition, its resistant elevation up to 3 weeks makes it very useful to estimate the radiation dose received and the severity of radiation-induced BM aplasia.
The AFRRI Biological Dosimetry Group has advocated transitioning the protein-and haematologybased approaches to deployable platforms to provide point-of-care and field-deployable diagnostics. Ongoing research at AFRRI has revealed a patentpending panel of radio-responsive protein biomarkers present in peripheral whole blood (5 -10) . The ongoing efforts are focused towards developing a new tool for assessing radiation exposure dose by measuring the responses of multiple plasma biomarkers and combined, using a multi-parametric algorithm, to calculate an exposed dose. A new tool might be minimally invasive (small drop-finger stick) and ideally self-administered.
The first point-of-care and field-deployable diagnostics device is the MSD MULTI-ARRAY w electrochemiluminescence detection technology platform for multiplexed immunoassays for the panel of radiation biomarkers (Meso Scale Discovery, Rockville, MD, USA) (48) . This detection technology enables arraybased multiplexed measurements to be carried out with high sensitivity and dynamic range (49) . The technology is in wide commercial use for multiplexed biomarker measurements for life science research and drug development and is also currently being incorporated into instrumentation designed for use in medical diagnostics both in point-of-care and high-throughput laboratory settings.
The second device is the SpinDx TM (Sandia National Labs, Livermore, CA, USA), a fully automated, deployable platform for assessing radiation exposure dose based on protein and haematological biomarkers present in peripheral whole blood. Small-volume whole blood samples ( 20 ml from finger puncture) are analysed with high sensitivity and wide dynamic ranges with a total sample-to-answer time of ,10 min. Preliminary studies with a TBI mouse model show strong correlation between SpinDx TM results and gold standard clinical analysis (50) . Both platforms are addressing the needs and current gap in FDA-approved rapid, deployable diagnostics in the event of a mass exposure radiation incident. The authors' expectations are that these research efforts will contribute to bridging a gap that exists in the current capabilities to rapidly and effectively identify and assess radiation exposure early after a radiation event, especially after a mass-casualty radiological incident.
Protein biomarkers are very useful in defining a radiation exposure, but many confounding factors exist that must be considered in their interpretation. Protein levels differ in several human cohorts, including individuals with HIV, rheumatoid arthritis, dialysis patients, bacteraemia and in a group of apparently healthy individuals during a marathon. These groups simulated a series of potentially confounding factors such as individual variability, pre-existing conditions and the effects of general physical stress on the levels of protein and nucleic acid transcript levels in blood. All these situations are relevant and potential factors that could influence an individual's response to radiation including co-exposure to infectious agents, physical stress from living in extreme environments and individual differences in response. Future studies are dedicated to finding a biomarker panel of radiation-responsive proteins unaffected by these situations to give accurate dose estimates.
